Key facts
- DNA SEQ’s last known valuation is $10.5M (Mar 2026).
- It has raised $1.2M; the latest was Seed Round ($1.2M) in Mar 2026.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for DNA SEQ
- ·The full record, as it builds
Funding rounds
No funding rounds for DNA SEQ are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DNA SEQ
Operator of a small molecule drug discovery company intended to offer to overcome the resistance of cancer to existing kinase inhibitors. The company's platform offers kinase inhibitors and cancer-blocking drugs thereby allowing people to extend their lives after being diagnosed with certain types of cancer with the mechanism of cancer resistance to targeted therapies and algorithmic approaches to creating a drug discovery platform.
- Sector
- Healthcare
- HQ
- La Mesa, CA, United States
- Founded
- 2022
- Website
- dnaseq.io/
- Ownership
- Privately Held (backing)
DNA SEQ doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DNA SEQ shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DNA SEQ in its N-PORT filings yet. We sweep new filings monthly.